文献速递骨肿瘤骨质疏松与代谢性骨病

改良格拉斯哥预后评分在软骨肉瘤患者管理中的预后价值:一项多中心研究

The prognostic value of the modified Glasgow Prognostic Score in the management of patients with chondrosarcoma : a multicentre study.
PubMed 文献 · Bone Joint J · 2025-06-01

这项英国七家骨肉瘤中心的多中心研究纳入2006年1月至2020年12月间接受择期切除的原发或继发性软骨肉瘤患者549例,随访至少两年,采用Kaplan-Meier生存分析及单因素和多因素分析,发现改良格拉斯哥预后评分(mGPS)升高、肿瘤分级、大小、年龄、局部复发、转移及炎症标志物与总生存期降低显著相关,mGPS可将所有级别软骨肉瘤患者的总生存期分层,作者推荐在早期评估中使用mGPS以更好地分层预后。

要点

  • 549例软骨肉瘤患者中,mGPS升高、肿瘤分级、大小、年龄、局部复发、转移及炎症标志物与总生存期降低显著相关。
  • mGPS可将所有级别软骨肉瘤患者的总生存期分层,尤其是mGPS评分0分与1或2分之间的区分。
  • 作者推荐在软骨肉瘤早期评估中使用mGPS以更好地分层预后、辅助决策并可能改善结局。

核心结论

  • 炎症标志物和mGPS与软骨肉瘤患者生存期强烈相关。
  • 作者推荐在软骨肉瘤早期评估中使用mGPS以更好地分层预后、辅助决策并可能改善结局。

研究设计与样本

  • 研究为英国七家骨肉瘤中心合作开展的国家多中心研究,纳入2006年1月至2020年12月间接受择期切除的原发或继发性软骨肉瘤患者549例。
  • 从前瞻性维护的数据库和患者记录中收集实验室与临床数据及肿瘤学结局,随访至少两年,采用Kaplan-Meier生存分析及单因素和多因素分析。

主要发现

  • mGPS升高、肿瘤分级、大小、年龄、局部复发、转移及炎症标志物与总生存期降低显著相关。
  • mGPS可将所有级别软骨肉瘤患者的总生存期分层,尤其是mGPS评分0分与1或2分之间的区分。

关键数值与推荐

  • mGPS为基于术前C反应蛋白和白蛋白的炎症预后评分,由mGPS评分0分与1或2分进行分层。

临床怎么用

  • 作者推荐在软骨肉瘤早期评估中使用mGPS以更好地分层预后、辅助决策并可能改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The prognostic role of systemic inflammatory biomarkers in patients with chondrosarcoma remains unclear, and evidence is lacking. The modified Glasgow Prognostic Score (mGPS) is an inflammation-based prognostic score consisting of preoperative CRP and albumin. This has been validated for a number of carcinomas and soft-tissue sarcoma, where its use is recommended. This national multicentre study aimed to investigate the prognostic significance of preoperative systemic inflammatory biomarkers, primarily the mGPS, in the prediction of survival in patients with a chondrosarcoma. METHODS: Patients who had undergone an elective resection of a primary or secondary chondrosarcoma between January 2006 and December 2020 were identified from the prospectively maintained databases of seven collaborating UK bone sarcoma units. Laboratory and clinical data, as well as oncological outcomes, were collected from the patient records with a minimum of two years of follow-up. Data were analyzed using Kaplan-Meier survival and uni- and multivariate analysis. RESULTS: A total of 549 patients were included in our study. We found that increased mGPS, tumour grade, size, age, local recurrence, metastasis, and inflammatory markers were significantly associated with reduced overall survival. mGPS was able to stratify the overall survival of patients in all grades of chondrosarcoma, especially when divided into mGPS score 0 versus mGPS 1 or 2. CONCLUSION: Our findings indicate that inflammatory markers and mGPS strongly correlate with the survival of patients with a chondrosarcoma. We recommend its use in their early assessment to better stratify prognosis, reinforce decision-making, and potentially improve outcomes.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Ben Gal O, Doonan J, Lotfi N, et al. The prognostic value of the modified Glasgow Prognostic Score in the management of patients with chondrosarcoma : a multicentre study. Bone Joint J. 2025. PMID: 40449541. doi:10.1302/0301-620X.107B6.BJJ-2024-0596.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。